



Thrombogenic Agents Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-23	142	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

Description

The global Thrombogenic Agents market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Thrombogenic Agents is projected to increase from US\$ million in 2026 to US\$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Thrombogenic Agents is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032.

The Asia Pacific market for Thrombogenic Agents is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Thrombogenic Agents include Chongqing Dikang Yangtze River Pharmaceutical, Zhongbao Pharmaceutical, Wuzhong Medicine Suzhou Pharmaceutical, Tiancheng Pharmaceutical Group, Shanghai RAAS Blood Products, Shandong Taibang Biotechnology, Sanofi, Nuokang Pharmaceutical Group and Novo Nordisk, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Thrombogenic Agents market in terms of revenue (US\$ million) and, where applicable, sales volume (units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US\$/units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Thrombogenic Agents Market by Company

Chongqing Dikang Yangtze River Pharmaceutical

Zhongbao Pharmaceutical
Wuzhong Medicine Suzhou Pharmaceutical
Tiancheng Pharmaceutical Group
Shanghai RAAS Blood Products
Shandong Taibang Biotechnology
Sanofi
Nuokang Pharmaceutical Group
Novo Nordisk
Merck
Roche
Chongqing Laimei Pharmaceutical
Jiangsu Yabang Aipson Pharmaceutical
Pfizer
Boya Biopharmaceutical
Amgen
AbbVie
Johnson And Johnson
BristolMyers Squibb
Boehringer Ingelheim

Thrombogenic Agents Segment by Type

Vitamin K Antagonists
Direct Thrombin Inhibitors
Antithrombin III Dependent Anticoagulants
Factor Xa Inhibitors
Others

Thrombogenic Agents Segment by Application

Tumor Treatment
Stop Bleeding
Cardiovascular Disease Treatment
Research And Drug Development
Others

Thrombogenic Agents Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden

Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Thrombogenic Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Thrombogenic Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Thrombogenic Agents.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Detailed analysis of Thrombogenic Agents manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5:

Production/output, value of Thrombogenic Agents by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6:

Consumption of Thrombogenic Agents in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7:

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8:

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9:

Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10:

Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
 - 2.2.1 Global Thrombogenic Agents Market Size (2021-2032)
 - 2.2.2 Global Thrombogenic Agents Sales (2021-2032)
 - 2.2.3 Global Thrombogenic Agents Market Average Price (2021-2032)
- 2.3 Thrombogenic Agents by Type
 - 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
 - 2.3.2 Vitamin K Antagonists
 - 2.3.3 Direct Thrombin Inhibitors
 - 2.3.4 Antithrombin III Dependent Anticoagulants
 - 2.3.5 Factor Xa Inhibitors
 - 2.3.6 Others
- 2.4 Thrombogenic Agents by Application
 - 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.4.2 Tumor Treatment
 - 2.4.3 Stop Bleeding
 - 2.4.4 Cardiovascular Disease Treatment
 - 2.4.5 Research And Drug Development
 - 2.4.6 Others

3 Market Competitive Landscape by Manufacturers

- 3.1 Global Thrombogenic Agents Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Thrombogenic Agents Sales (units) of Manufacturers (2021-2026)
- 3.3 Global Thrombogenic Agents Revenue of Manufacturers (2021-2026)
- 3.4 Global Thrombogenic Agents Average Price by Manufacturers (2021-2026)
- 3.5 Global Thrombogenic Agents Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Thrombogenic Agents, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Thrombogenic Agents, Product Type & Application
- 3.8 Global Manufacturers of Thrombogenic Agents, Established Date
- 3.9 Global Thrombogenic Agents Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition

4 Manufacturers Profiled

- 4.1 Chongqing Dikang Yangtze River Pharmaceutical
 - 4.1.1 Chongqing Dikang Yangtze River Pharmaceutical Company Information
 - 4.1.2 Chongqing Dikang Yangtze River Pharmaceutical Business Overview

- 4.1.3 Chongqing Dikang Yangtze River Pharmaceutical Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Chongqing Dikang Yangtze River Pharmaceutical Thrombogenic Agents Product Portfolio
- 4.1.5 Chongqing Dikang Yangtze River Pharmaceutical Recent Developments
- 4.2 Zhongbao Pharmaceutical
 - 4.2.1 Zhongbao Pharmaceutical Company Information
 - 4.2.2 Zhongbao Pharmaceutical Business Overview
 - 4.2.3 Zhongbao Pharmaceutical Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
 - 4.2.4 Zhongbao Pharmaceutical Thrombogenic Agents Product Portfolio
 - 4.2.5 Zhongbao Pharmaceutical Recent Developments
- 4.3 Wuzhong Medicine Suzhou Pharmaceutical
 - 4.3.1 Wuzhong Medicine Suzhou Pharmaceutical Company Information
 - 4.3.2 Wuzhong Medicine Suzhou Pharmaceutical Business Overview
 - 4.3.3 Wuzhong Medicine Suzhou Pharmaceutical Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
 - 4.3.4 Wuzhong Medicine Suzhou Pharmaceutical Thrombogenic Agents Product Portfolio
 - 4.3.5 Wuzhong Medicine Suzhou Pharmaceutical Recent Developments
- 4.4 Tiancheng Pharmaceutical Group
 - 4.4.1 Tiancheng Pharmaceutical Group Company Information
 - 4.4.2 Tiancheng Pharmaceutical Group Business Overview
 - 4.4.3 Tiancheng Pharmaceutical Group Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
 - 4.4.4 Tiancheng Pharmaceutical Group Thrombogenic Agents Product Portfolio
 - 4.4.5 Tiancheng Pharmaceutical Group Recent Developments
- 4.5 Shanghai RAAS Blood Products
 - 4.5.1 Shanghai RAAS Blood Products Company Information
 - 4.5.2 Shanghai RAAS Blood Products Business Overview
 - 4.5.3 Shanghai RAAS Blood Products Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
 - 4.5.4 Shanghai RAAS Blood Products Thrombogenic Agents Product Portfolio
 - 4.5.5 Shanghai RAAS Blood Products Recent Developments
- 4.6 Shandong Taibang Biotechnology
 - 4.6.1 Shandong Taibang Biotechnology Company Information
 - 4.6.2 Shandong Taibang Biotechnology Business Overview
 - 4.6.3 Shandong Taibang Biotechnology Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
 - 4.6.4 Shandong Taibang Biotechnology Thrombogenic Agents Product Portfolio
 - 4.6.5 Shandong Taibang Biotechnology Recent Developments
- 4.7 Sanofi
 - 4.7.1 Sanofi Company Information
 - 4.7.2 Sanofi Business Overview
 - 4.7.3 Sanofi Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
 - 4.7.4 Sanofi Thrombogenic Agents Product Portfolio
 - 4.7.5 Sanofi Recent Developments
- 4.8 Nuokang Pharmaceutical Group
 - 4.8.1 Nuokang Pharmaceutical Group Company Information
 - 4.8.2 Nuokang Pharmaceutical Group Business Overview
 - 4.8.3 Nuokang Pharmaceutical Group Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
 - 4.8.4 Nuokang Pharmaceutical Group Thrombogenic Agents Product Portfolio
 - 4.8.5 Nuokang Pharmaceutical Group Recent Developments
- 4.9 Novo Nordisk
 - 4.9.1 Novo Nordisk Company Information

- 4.9.2 Novo Nordisk Business Overview
- 4.9.3 Novo Nordisk Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Novo Nordisk Thrombogenic Agents Product Portfolio
- 4.9.5 Novo Nordisk Recent Developments
- 4.10 Merck
 - 4.10.1 Merck Company Information
 - 4.10.2 Merck Business Overview
 - 4.10.3 Merck Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
 - 4.10.4 Merck Thrombogenic Agents Product Portfolio
 - 4.10.5 Merck Recent Developments
- 4.11 Roche
 - 4.11.1 Roche Company Information
 - 4.11.2 Roche Business Overview
 - 4.11.3 Roche Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
 - 4.11.4 Roche Thrombogenic Agents Product Portfolio
 - 4.11.5 Roche Recent Developments
- 4.12 Chongqing Laimei Pharmaceutical
 - 4.12.1 Chongqing Laimei Pharmaceutical Company Information
 - 4.12.2 Chongqing Laimei Pharmaceutical Business Overview
 - 4.12.3 Chongqing Laimei Pharmaceutical Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
 - 4.12.4 Chongqing Laimei Pharmaceutical Thrombogenic Agents Product Portfolio
 - 4.12.5 Chongqing Laimei Pharmaceutical Recent Developments
- 4.13 Jiangsu Yabang Aipson Pharmaceutical
 - 4.13.1 Jiangsu Yabang Aipson Pharmaceutical Company Information
 - 4.13.2 Jiangsu Yabang Aipson Pharmaceutical Business Overview
 - 4.13.3 Jiangsu Yabang Aipson Pharmaceutical Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
 - 4.13.4 Jiangsu Yabang Aipson Pharmaceutical Thrombogenic Agents Product Portfolio
 - 4.13.5 Jiangsu Yabang Aipson Pharmaceutical Recent Developments
- 4.14 Pfizer
 - 4.14.1 Pfizer Company Information
 - 4.14.2 Pfizer Business Overview
 - 4.14.3 Pfizer Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
 - 4.14.4 Pfizer Thrombogenic Agents Product Portfolio
 - 4.14.5 Pfizer Recent Developments
- 4.15 Boya Biopharmaceutical
 - 4.15.1 Boya Biopharmaceutical Company Information
 - 4.15.2 Boya Biopharmaceutical Business Overview
 - 4.15.3 Boya Biopharmaceutical Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
 - 4.15.4 Boya Biopharmaceutical Thrombogenic Agents Product Portfolio
 - 4.15.5 Boya Biopharmaceutical Recent Developments
- 4.16 Amgen
 - 4.16.1 Amgen Company Information
 - 4.16.2 Amgen Business Overview
 - 4.16.3 Amgen Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
 - 4.16.4 Amgen Thrombogenic Agents Product Portfolio
 - 4.16.5 Amgen Recent Developments
- 4.17 AbbVie
 - 4.17.1 AbbVie Company Information

- 4.17.2 AbbVie Business Overview
- 4.17.3 AbbVie Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 AbbVie Thrombogenic Agents Product Portfolio
- 4.17.5 AbbVie Recent Developments

4.18 Johnson And Johnson

- 4.18.1 Johnson And Johnson Company Information
- 4.18.2 Johnson And Johnson Business Overview
- 4.18.3 Johnson And Johnson Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Johnson And Johnson Thrombogenic Agents Product Portfolio
- 4.18.5 Johnson And Johnson Recent Developments

4.19 BristolMyers Squibb

- 4.19.1 BristolMyers Squibb Company Information
- 4.19.2 BristolMyers Squibb Business Overview
- 4.19.3 BristolMyers Squibb Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.19.4 BristolMyers Squibb Thrombogenic Agents Product Portfolio
- 4.19.5 BristolMyers Squibb Recent Developments

4.20 Boehringer Ingelheim

- 4.20.1 Boehringer Ingelheim Company Information
- 4.20.2 Boehringer Ingelheim Business Overview
- 4.20.3 Boehringer Ingelheim Thrombogenic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.20.4 Boehringer Ingelheim Thrombogenic Agents Product Portfolio
- 4.20.5 Boehringer Ingelheim Recent Developments

5 Global Thrombogenic Agents Market Scenario by Region

5.1 Global Thrombogenic Agents Market Size by Region: 2021 VS 2025 VS 2032

5.2 Global Thrombogenic Agents Sales by Region: 2021-2032

- 5.2.1 Global Thrombogenic Agents Sales by Region: 2021-2026
- 5.2.2 Global Thrombogenic Agents Sales by Region: 2027-2032

5.3 Global Thrombogenic Agents Revenue by Region: 2021-2032

- 5.3.1 Global Thrombogenic Agents Revenue by Region: 2021-2026
- 5.3.2 Global Thrombogenic Agents Revenue by Region: 2027-2032

5.4 North America Thrombogenic Agents Market Facts & Figures by Country

- 5.4.1 North America Thrombogenic Agents Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Thrombogenic Agents Sales by Country (2021-2032)
- 5.4.3 North America Thrombogenic Agents Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico

5.5 Europe Thrombogenic Agents Market Facts & Figures by Country

- 5.5.1 Europe Thrombogenic Agents Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Thrombogenic Agents Sales by Country (2021-2032)
- 5.5.3 Europe Thrombogenic Agents Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands

5.5.11 Switzerland

5.5.12 Sweden

5.5.13 Poland

5.6 Asia Pacific Thrombogenic Agents Market Facts & Figures by Country

5.6.1 Asia Pacific Thrombogenic Agents Market Size by Country: 2021 VS 2025 VS 2032

5.6.2 Asia Pacific Thrombogenic Agents Sales by Country (2021-2032)

5.6.3 Asia Pacific Thrombogenic Agents Revenue by Country (2021-2032)

5.6.4 China

5.6.5 Japan

5.6.6 South Korea

5.6.7 India

5.6.8 Australia

5.6.9 Taiwan

5.6.10 Southeast Asia

5.7 South America Thrombogenic Agents Market Facts & Figures by Country

5.7.1 South America Thrombogenic Agents Market Size by Country: 2021 VS 2025 VS 2032

5.7.2 South America Thrombogenic Agents Sales by Country (2021-2032)

5.7.3 South America Thrombogenic Agents Revenue by Country (2021-2032)

5.7.4 Brazil

5.7.5 Argentina

5.7.6 Chile

5.8 Middle East and Africa Thrombogenic Agents Market Facts & Figures by Country

5.8.1 Middle East and Africa Thrombogenic Agents Market Size by Country: 2021 VS 2025 VS 2032

5.8.2 Middle East and Africa Thrombogenic Agents Sales by Country (2021-2032)

5.8.3 Middle East and Africa Thrombogenic Agents Revenue by Country (2021-2032)

5.8.4 Egypt

5.8.5 South Africa

5.8.6 Israel

5.8.7 Türkiye

5.8.8 GCC Countries

6 Segment by Type

6.1 Global Thrombogenic Agents Sales by Type (2021-2032)

6.1.1 Global Thrombogenic Agents Sales by Type (2021-2032) & (units)

6.1.2 Global Thrombogenic Agents Sales Market Share by Type (2021-2032)

6.2 Global Thrombogenic Agents Revenue by Type (2021-2032)

6.2.1 Global Thrombogenic Agents Sales by Type (2021-2032) & (US\$ Million)

6.2.2 Global Thrombogenic Agents Revenue Market Share by Type (2021-2032)

6.3 Global Thrombogenic Agents Price by Type (2021-2032)

7 Segment by Application

7.1 Global Thrombogenic Agents Sales by Application (2021-2032)

7.1.1 Global Thrombogenic Agents Sales by Application (2021-2032) & (units)

7.1.2 Global Thrombogenic Agents Sales Market Share by Application (2021-2032)

7.2 Global Thrombogenic Agents Revenue by Application (2021-2032)

7.2.1 Global Thrombogenic Agents Sales by Application (2021-2032) & (US\$ Million)

7.2.2 Global Thrombogenic Agents Revenue Market Share by Application (2021-2032)

7.3 Global Thrombogenic Agents Price by Application (2021-2032)

8 Value Chain and Sales Channels Analysis of the Market

8.1 Thrombogenic Agents Value Chain Analysis

8.1.1 Thrombogenic Agents Key Raw Materials

8.1.2 Raw Materials Key Suppliers

8.1.3 Thrombogenic Agents Production Mode & Process

8.2 Thrombogenic Agents Sales Channels Analysis

8.2.1 Direct Comparison with Distribution Share

8.2.2 Thrombogenic Agents Distributors

8.2.3 Thrombogenic Agents Customers

9 Global Thrombogenic Agents Analyzing Market Dynamics

9.1 Thrombogenic Agents Industry Trends

9.2 Thrombogenic Agents Industry Drivers

9.3 Thrombogenic Agents Industry Opportunities and Challenges

9.4 Thrombogenic Agents Industry Restraints

10 Report Conclusion

11 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Thrombogenic Agents Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
- Table 6: Global Thrombogenic Agents Sales (units) of Manufacturers (2021-2026)
- Table 7: Global Thrombogenic Agents Sales Market Share by Manufacturers (2021-2026)
- Table 8: Global Thrombogenic Agents Revenue of Manufacturers (2021-2026)
- Table 9: Global Thrombogenic Agents Revenue Share by Manufacturers (2021-2026)
- Table 10: Global Market Thrombogenic Agents Average Price (USD/unit) of Manufacturers (2021-2026)
- Table 11: Global Thrombogenic Agents Industry Ranking, 2024 VS 2025 VS 2026
- Table 12: Global Manufacturers of Thrombogenic Agents, Manufacturing Sites & Headquarters
- Table 13: Global Manufacturers of Thrombogenic Agents, Product Type & Application
- Table 14: Global Thrombogenic Agents Manufacturers Established Date
- Table 15: Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16: Global Thrombogenic Agents by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 17: Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18: Chongqing Dikang Yangtze River Pharmaceutical Company Information
- Table 19: Chongqing Dikang Yangtze River Pharmaceutical Business Overview
- Table 20: Chongqing Dikang Yangtze River Pharmaceutical Thrombogenic Agents Sales (units), Revenue (US\$ Million), Price (USD/unit) and Gross Margin (2021-2026)
- Table 21: Chongqing Dikang Yangtze River Pharmaceutical Thrombogenic Agents Product Portfolio
- Table 22: Chongqing Dikang Yangtze River Pharmaceutical Recent Developments
- Table 23: Zhongbao Pharmaceutical Company Information
- Table 24: Zhongbao Pharmaceutical Business Overview
- Table 25: Zhongbao Pharmaceutical Thrombogenic Agents Sales (units), Revenue (US\$ Million), Price (USD/unit) and Gross Margin (2021-2026)
- Table 26: Zhongbao Pharmaceutical Thrombogenic Agents Product Portfolio
- Table 27: Zhongbao Pharmaceutical Recent Developments
- Table 28: Wuzhong Medicine Suzhou Pharmaceutical Company Information
- Table 29: Wuzhong Medicine Suzhou Pharmaceutical Business Overview
- Table 30: Wuzhong Medicine Suzhou Pharmaceutical Thrombogenic Agents Sales (units), Revenue (US\$ Million), Price (USD/unit) and Gross Margin (2021-2026)
- Table 31: Wuzhong Medicine Suzhou Pharmaceutical Thrombogenic Agents Product Portfolio
- Table 32: Wuzhong Medicine Suzhou Pharmaceutical Recent Developments
- Table 33: Tiancheng Pharmaceutical Group Company Information
- Table 34: Tiancheng Pharmaceutical Group Business Overview
- Table 35: Tiancheng Pharmaceutical Group Thrombogenic Agents Sales (units), Revenue (US\$ Million), Price (USD/unit) and Gross Margin (2021-2026)
- Table 36: Tiancheng Pharmaceutical Group Thrombogenic Agents Product Portfolio
- Table 37: Tiancheng Pharmaceutical Group Recent Developments
- Table 38: Shanghai RAAS Blood Products Company Information
- Table 39: Shanghai RAAS Blood Products Business Overview
- Table 40: Shanghai RAAS Blood Products Thrombogenic Agents Sales (units), Revenue (US\$ Million), Price (USD/unit) and Gross Margin (2021-2026)
- Table 41: Shanghai RAAS Blood Products Thrombogenic Agents Product Portfolio
- Table 42: Shanghai RAAS Blood Products Recent Developments
- Table 43: Shandong Taibang Biotechnology Company Information
- Table 44: Shandong Taibang Biotechnology Business Overview
- Table 45: Shandong Taibang Biotechnology Thrombogenic Agents Sales (units), Revenue (US\$ Million), Price (USD/unit) and Gross Margin (2021-2026)
- Table 46: Shandong Taibang Biotechnology Thrombogenic Agents Product Portfolio
- Table 47: Shandong Taibang Biotechnology Recent Developments
- Table 48: Sanofi Company Information
- Table 49: Sanofi Business Overview

- Table 50: Sanofi Thrombogenic Agents Sales (units), Revenue (US\$ Million), Price (USD/unit) and Gross Margin (2021-2026)
- Table 51: Sanofi Thrombogenic Agents Product Portfolio
- Table 52: Sanofi Recent Developments
- Table 53: Nuokang Pharmaceutical Group Company Information
- Table 54: Nuokang Pharmaceutical Group Business Overview
- Table 55: Nuokang Pharmaceutical Group Thrombogenic Agents Sales (units), Revenue (US\$ Million), Price (USD/unit) and Gross Margin (2021-2026)
- Table 56: Nuokang Pharmaceutical Group Thrombogenic Agents Product Portfolio
- Table 57: Nuokang Pharmaceutical Group Recent Developments
- Table 58: Novo Nordisk Company Information
- Table 59: Novo Nordisk Business Overview
- Table 60: Novo Nordisk Thrombogenic Agents Sales (units), Revenue (US\$ Million), Price (USD/unit) and Gross Margin (2021-2026)
- Table 61: Novo Nordisk Thrombogenic Agents Product Portfolio
- Table 62: Novo Nordisk Recent Developments
- Table 63: Merck Company Information
- Table 64: Merck Business Overview
- Table 65: Merck Thrombogenic Agents Sales (units), Revenue (US\$ Million), Price (USD/unit) and Gross Margin (2021-2026)
- Table 66: Merck Thrombogenic Agents Product Portfolio
- Table 67: Merck Recent Developments
- Table 68: Roche Company Information
- Table 69: Roche Business Overview
- Table 70: Roche Thrombogenic Agents Sales (units), Revenue (US\$ Million), Price (USD/unit) and Gross Margin (2021-2026)
- Table 71: Roche Thrombogenic Agents Product Portfolio
- Table 72: Roche Recent Developments
- Table 73: Chongqing Laimei Pharmaceutical Company Information
- Table 74: Chongqing Laimei Pharmaceutical Business Overview
- Table 75: Chongqing Laimei Pharmaceutical Thrombogenic Agents Sales (units), Revenue (US\$ Million), Price (USD/unit) and Gross Margin (2021-2026)
- Table 76: Chongqing Laimei Pharmaceutical Thrombogenic Agents Product Portfolio
- Table 77: Chongqing Laimei Pharmaceutical Recent Developments
- Table 78: Jiangsu Yabang Aipson Pharmaceutical Company Information
- Table 79: Jiangsu Yabang Aipson Pharmaceutical Business Overview
- Table 80: Jiangsu Yabang Aipson Pharmaceutical Thrombogenic Agents Sales (units), Revenue (US\$ Million), Price (USD/unit) and Gross Margin (2021-2026)
- Table 81: Jiangsu Yabang Aipson Pharmaceutical Thrombogenic Agents Product Portfolio
- Table 82: Jiangsu Yabang Aipson Pharmaceutical Recent Developments
- Table 83: Pfizer Company Information
- Table 84: Pfizer Business Overview
- Table 85: Pfizer Thrombogenic Agents Sales (units), Revenue (US\$ Million), Price (USD/unit) and Gross Margin (2021-2026)
- Table 86: Pfizer Thrombogenic Agents Product Portfolio
- Table 87: Pfizer Recent Developments
- Table 88: Boya Biopharmaceutical Company Information
- Table 89: Boya Biopharmaceutical Business Overview
- Table 90: Boya Biopharmaceutical Thrombogenic Agents Sales (units), Revenue (US\$ Million), Price (USD/unit) and Gross Margin (2021-2026)
- Table 91: Boya Biopharmaceutical Thrombogenic Agents Product Portfolio
- Table 92: Boya Biopharmaceutical Recent Developments
- Table 93: Amgen Company Information
- Table 94: Amgen Business Overview
- Table 95: Amgen Thrombogenic Agents Sales (units), Revenue (US\$ Million), Price (USD/unit) and Gross Margin (2021-2026)
- Table 96: Amgen Thrombogenic Agents Product Portfolio
- Table 97: Amgen Recent Developments
- Table 98: AbbVie Company Information
- Table 99: AbbVie Business Overview
- Table 100: AbbVie Thrombogenic Agents Sales (units), Revenue (US\$ Million), Price (USD/unit) and Gross Margin (2021-2026)
- Table 101: AbbVie Thrombogenic Agents Product Portfolio
- Table 102: AbbVie Recent Developments
- Table 103: Johnson And Johnson Company Information
- Table 104: Johnson And Johnson Business Overview
- Table 105: Johnson And Johnson Thrombogenic Agents Sales (units), Revenue (US\$ Million), Price (USD/unit) and Gross Margin (2021-2026)
- Table 106: Johnson And Johnson Thrombogenic Agents Product Portfolio
- Table 107: Johnson And Johnson Recent Developments

- Table 108: BristolMyers Squibb Company Information
- Table 109: BristolMyers Squibb Business Overview
- Table 110: BristolMyers Squibb Thrombogenic Agents Sales (units), Revenue (US\$ Million), Price (USD/unit) and Gross Margin (2021-2026)
- Table 111: BristolMyers Squibb Thrombogenic Agents Product Portfolio
- Table 112: BristolMyers Squibb Recent Developments
- Table 113: Boehringer Ingelheim Company Information
- Table 114: Boehringer Ingelheim Business Overview
- Table 115: Boehringer Ingelheim Thrombogenic Agents Sales (units), Revenue (US\$ Million), Price (USD/unit) and Gross Margin (2021-2026)
- Table 116: Boehringer Ingelheim Thrombogenic Agents Product Portfolio
- Table 117: Boehringer Ingelheim Recent Developments
- Table 118: Global Thrombogenic Agents Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 119: Global Thrombogenic Agents Sales by Region (2021-2026) & (units)
- Table 120: Global Thrombogenic Agents Sales Market Share by Region (2021-2026)
- Table 121: Global Thrombogenic Agents Sales by Region (2027-2032) & (units)
- Table 122: Global Thrombogenic Agents Sales Market Share by Region (2027-2032)
- Table 123: Global Thrombogenic Agents Revenue by Region (2021-2026) & (US\$ Million)
- Table 124: Global Thrombogenic Agents Revenue Market Share by Region (2021-2026)
- Table 125: Global Thrombogenic Agents Revenue by Region (2027-2032) & (US\$ Million)
- Table 126: Global Thrombogenic Agents Revenue Market Share by Region (2027-2032)
- Table 127: North America Thrombogenic Agents Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 128: North America Thrombogenic Agents Sales by Country (2021-2026) & (units)
- Table 129: North America Thrombogenic Agents Sales by Country (2027-2032) & (units)
- Table 130: North America Thrombogenic Agents Revenue by Country (2021-2026) & (US\$ Million)
- Table 131: North America Thrombogenic Agents Revenue by Country (2027-2032) & (US\$ Million)
- Table 132: Europe Thrombogenic Agents Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 133: Europe Thrombogenic Agents Sales by Country (2021-2026) & (units)
- Table 134: Europe Thrombogenic Agents Sales by Country (2027-2032) & (units)
- Table 135: Europe Thrombogenic Agents Revenue by Country (2021-2026) & (US\$ Million)
- Table 136: Europe Thrombogenic Agents Revenue by Country (2027-2032) & (US\$ Million)
- Table 137: Asia Pacific Thrombogenic Agents Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 138: Asia Pacific Thrombogenic Agents Sales by Country (2021-2026) & (units)
- Table 139: Asia Pacific Thrombogenic Agents Sales by Country (2027-2032) & (units)
- Table 140: Asia Pacific Thrombogenic Agents Revenue by Country (2021-2026) & (US\$ Million)
- Table 141: Asia Pacific Thrombogenic Agents Revenue by Country (2027-2032) & (US\$ Million)
- Table 142: South America Thrombogenic Agents Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 143: South America Thrombogenic Agents Sales by Country (2021-2026) & (units)
- Table 144: South America Thrombogenic Agents Sales by Country (2027-2032) & (units)
- Table 145: South America Thrombogenic Agents Revenue by Country (2021-2026) & (US\$ Million)
- Table 146: South America Thrombogenic Agents Revenue by Country (2027-2032) & (US\$ Million)
- Table 147: Middle East and Africa Thrombogenic Agents Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 148: Middle East and Africa Thrombogenic Agents Sales by Country (2021-2026) & (units)
- Table 149: Middle East and Africa Thrombogenic Agents Sales by Country (2027-2032) & (units)
- Table 150: Middle East and Africa Thrombogenic Agents Revenue by Country (2021-2026) & (US\$ Million)
- Table 151: Middle East and Africa Thrombogenic Agents Revenue by Country (2027-2032) & (US\$ Million)
- Table 152: Global Thrombogenic Agents Sales by Type (2021-2026) & (units)
- Table 153: Global Thrombogenic Agents Sales by Type (2027-2032) & (units)
- Table 154: Global Thrombogenic Agents Sales Market Share by Type (2021-2026)
- Table 155: Global Thrombogenic Agents Sales Market Share by Type (2027-2032)
- Table 156: Global Thrombogenic Agents Revenue by Type (2021-2026) & (US\$ Million)
- Table 157: Global Thrombogenic Agents Revenue by Type (2027-2032) & (US\$ Million)
- Table 158: Global Thrombogenic Agents Revenue Market Share by Type (2021-2026)
- Table 159: Global Thrombogenic Agents Revenue Market Share by Type (2027-2032)
- Table 160: Global Thrombogenic Agents Price by Type (2021-2026) & (USD/unit)
- Table 161: Global Thrombogenic Agents Price by Type (2027-2032) & (USD/unit)
- Table 162: Global Thrombogenic Agents Sales by Application (2021-2026) & (units)
- Table 163: Global Thrombogenic Agents Sales by Application (2027-2032) & (units)
- Table 164: Global Thrombogenic Agents Sales Market Share by Application (2021-2026)
- Table 165: Global Thrombogenic Agents Sales Market Share by Application (2027-2032)
- Table 166: Global Thrombogenic Agents Revenue by Application (2021-2026) & (US\$ Million)
- Table 167: Global Thrombogenic Agents Revenue by Application (2027-2032) & (US\$ Million)
- Table 168: Global Thrombogenic Agents Revenue Market Share by Application (2021-2026)
- Table 169: Global Thrombogenic Agents Revenue Market Share by Application (2027-2032)
- Table 170: Global Thrombogenic Agents Price by Application (2021-2026) & (USD/unit)

- Table 171: Global Thrombogenic Agents Price by Application (2027-2032) & (USD/unit)
- Table 172: Key Raw Materials
- Table 173: Raw Materials Key Suppliers
- Table 174: Thrombogenic Agents Distributors List
- Table 175: Thrombogenic Agents Customers List
- Table 176: Thrombogenic Agents Industry Trends
- Table 177: Thrombogenic Agents Industry Drivers
- Table 178: Thrombogenic Agents Industry Restraints
- Table 179: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Thrombogenic Agents Product Image
- Figure 5: Global Thrombogenic Agents Revenue (US\$ Million), 2021 VS 2025 VS 2032
- Figure 6: Global Thrombogenic Agents Market Size (2021-2032) & (US\$ Million)
- Figure 7: Global Thrombogenic Agents Sales (2021-2032) & (units)
- Figure 8: Global Thrombogenic Agents Average Price (USD/unit) & (2021-2032)
- Figure 9: Vitamin K Antagonists Product Image
- Figure 10: Direct Thrombin Inhibitors Product Image
- Figure 11: Antithrombin III Dependent Anticoagulants Product Image
- Figure 12: Factor Xa Inhibitors Product Image
- Figure 13: Others Product Image
- Figure 14: Tumor Treatment Product Image
- Figure 15: Stop Bleeding Product Image
- Figure 16: Cardiovascular Disease Treatment Product Image
- Figure 17: Research And Drug Development Product Image
- Figure 18: Others Product Image
- Figure 19: Global Thrombogenic Agents Revenue Share by Manufacturers in 2025
- Figure 20: Global Manufacturers of Thrombogenic Agents, Manufacturing Sites & Headquarters
- Figure 21: Global Top 5 and 10 Thrombogenic Agents Players Market Share by Revenue in 2025
- Figure 22: Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 23: Global Thrombogenic Agents Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Figure 24: Global Thrombogenic Agents Sales by Region in 2025
- Figure 25: Global Thrombogenic Agents Revenue by Region in 2025
- Figure 26: North America Thrombogenic Agents Market Size by Country in 2025
- Figure 27: North America Thrombogenic Agents Sales Market Share by Country (2021-2032)
- Figure 28: North America Thrombogenic Agents Revenue Market Share by Country (2021-2032)
- Figure 29: United States Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 30: Canada Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 31: Mexico Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 32: Europe Thrombogenic Agents Market Size by Country in 2025
- Figure 33: Europe Thrombogenic Agents Sales Market Share by Country (2021-2032)
- Figure 34: Europe Thrombogenic Agents Revenue Market Share by Country (2021-2032)
- Figure 35: Germany Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 36: France Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 37: U.K. Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 38: Italy Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 39: Russia Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 40: Spain Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 41: Netherlands Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 42: Switzerland Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 43: Sweden Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 44: Poland Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 45: Asia Pacific Thrombogenic Agents Market Size by Country in 2025
- Figure 46: Asia Pacific Thrombogenic Agents Sales Market Share by Country (2021-2032)
- Figure 47: Asia Pacific Thrombogenic Agents Revenue Market Share by Country (2021-2032)
- Figure 48: China Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 49: Japan Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 50: South Korea Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 51: India Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 52: Australia Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)

- Figure 53: Taiwan Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 54: Southeast Asia Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 55: Southeast Asia Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 56: South America Thrombogenic Agents Market Size by Country in 2025
- Figure 57: South America Thrombogenic Agents Sales Market Share by Country (2021-2032)
- Figure 58: South America Thrombogenic Agents Revenue Market Share by Country (2021-2032)
- Figure 59: Brazil Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 60: Argentina Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 61: Chile Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 62: Middle East and Africa Thrombogenic Agents Market Size by Country in 2025
- Figure 63: Middle East and Africa Thrombogenic Agents Sales Market Share by Country (2021-2032)
- Figure 64: Middle East and Africa Thrombogenic Agents Revenue Market Share by Country (2021-2032)
- Figure 65: Egypt Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 66: South Africa Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 67: Israel Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 68: Türkiye Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 69: GCC Countries Thrombogenic Agents Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 70: Global Thrombogenic Agents Sales Market Share by Type (2021-2032)
- Figure 71: Global Thrombogenic Agents Revenue Market Share by Type (2021-2032)
- Figure 72: Global Thrombogenic Agents Price (USD/unit) by Type (2021-2032)
- Figure 73: Global Thrombogenic Agents Sales Market Share by Application (2021-2032)
- Figure 74: Global Thrombogenic Agents Revenue Market Share by Application (2021-2032)
- Figure 75: Global Thrombogenic Agents Price (USD/unit) by Application (2021-2032)
- Figure 76: Thrombogenic Agents Value Chain
- Figure 77: Thrombogenic Agents Production Mode & Process
- Figure 78: Direct Comparison with Distribution Share
- Figure 79: Distributors Profiles
- Figure 80: Thrombogenic Agents Industry Opportunities and Challenges